» Articles » PMID: 22253424

Disruption of the Murine Glp2r Impairs Paneth Cell Function and Increases Susceptibility to Small Bowel Enteritis

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2012 Jan 19
PMID 22253424
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Exogenous glucagon-like peptide-2 receptor (GLP-2R) activation elicits proliferative and cytoprotective responses in the gastrointestinal mucosa and ameliorates experimental small and large bowel gut injury. Nevertheless, the essential physiological role(s) of the endogenous GLP-2R remain poorly understood. We studied the importance of the GLP-2R for gut growth, epithelial cell lineage allocation, the response to mucosal injury, and host-bacterial interactions in Glp2r(-/-) and littermate control Glp2r(+/+) mice. Glp2r(-/-) mice exhibit normal somatic growth and preserved small and large bowel responses to IGF-I and keratinocyte growth factor. However, Glp2r(-/-) mice failed to up-regulate intestinal epithelial c-fos expression in response to acute GLP-2 administration and do not exhibit changes in small bowel conductance or small or large bowel growth after administration of GLP-2R agonists. The crypt and villus compartment and the numbers and localization of Paneth, enteroendocrine, and goblet cells were comparable in Glp2r(+/+) vs. Glp2r(-/-) mice. Although the severity and extent of colonic mucosal injury in response to 3% oral dextran sulfate was similar across Glp2r genotypes, Glp2r(-/-) mice exhibited significantly increased morbidity and mortality and increased bacterial translocation after induction of enteritis with indomethacin and enhanced mucosal injury in response to irinotecan. Moreover, bacterial colonization of the small bowel was significantly increased, expression of Paneth cell antimicrobial gene products was reduced, and mucosal bactericidal activity was impaired in Glp2r(-/-) mice. Although the Glp2r is dispensable for gut development and the response to colonic injury, Glp2r(-/-) mice exhibit enhanced sensitivity to small bowel injury, and abnormal host-bacterial interactions in the small bowel.

Citing Articles

Multi-omics revealed that the postbiotic of hawthorn-probiotic alleviated constipation caused by loperamide in elderly mice.

Wei Y, Chen S, Ling Y, Wang W, Huang Y Front Nutr. 2025; 12:1498004.

PMID: 40070478 PMC: 11895004. DOI: 10.3389/fnut.2025.1498004.


Novel homozygous nonsense mutation in glucagon-like peptide-2 receptor gene resulting in severe human illness.

Jaramishian C, Kamal S, Martin M, Minkoff N JPGN Rep. 2024; 5(4):488-490.

PMID: 39610412 PMC: 11600376. DOI: 10.1002/jpr3.12125.


Enteroendocrine cells regulate intestinal homeostasis and epithelial function.

Nwako J, McCauley H Mol Cell Endocrinol. 2024; 593:112339.

PMID: 39111616 PMC: 11401774. DOI: 10.1016/j.mce.2024.112339.


Parenteral Nutrition, Inflammatory Bowel Disease, and Gut Barrier: An Intricate Plot.

Covello C, Becherucci G, Di Vincenzo F, Del Gaudio A, Pizzoferrato M, Cammarota G Nutrients. 2024; 16(14).

PMID: 39064731 PMC: 11279609. DOI: 10.3390/nu16142288.


Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.

Skarbaliene J, Mathiesen J, Larsen B, Thorkildsen C, Petersen Y BMC Gastroenterol. 2023; 23(1):79.

PMID: 36944922 PMC: 10029296. DOI: 10.1186/s12876-023-02716-4.


References
1.
Thulesen J, Knudsen L, Hartmann B, Hastrup S, Kissow H, Jeppesen P . The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept. 2001; 103(1):9-15. DOI: 10.1016/s0167-0115(01)00316-0. View

2.
Hsieh J, Longuet C, Maida A, Bahrami J, Xu E, Baker C . Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36. Gastroenterology. 2009; 137(3):997-1005, 1005.e1-4. DOI: 10.1053/j.gastro.2009.05.051. View

3.
Bahrami J, Longuet C, Baggio L, Li K, Drucker D . Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology. 2010; 139(3):857-68. DOI: 10.1053/j.gastro.2010.05.006. View

4.
Jeppesen P, Gilroy R, Pertkiewicz M, Allard J, Messing B, OKeefe S . Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut. 2011; 60(7):902-14. PMC: 3112364. DOI: 10.1136/gut.2010.218271. View

5.
Bremholm L, Hornum M, Henriksen B, Larsen S, Holst J . Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol. 2008; 44(3):314-9. DOI: 10.1080/00365520802538195. View